From Karyopharm Grabs $48.2M Series B to Advance Cancer Drugs:

Karyopharm

Karyopharm—

Karyopharm Therapeutics is developing cancer drugs.

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

From Our Editors · Special Report
Xcelerating Life Sciences San Diego: Special Report
Learn what's fueling San Diego's biotech investment and partnership opportunities

Xconomy on Demand

We offer a number of ways to subscribe for free!